GSK plc GLAXF
OTC PK
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.96% | 8.78% | 9.20% | 7.52% | 5.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.96% | 8.78% | 9.20% | 7.52% | 5.90% |
| Cost of Revenue | 1.83% | 1.80% | 5.39% | 4.47% | 5.66% |
| Gross Profit | 8.91% | 11.55% | 10.68% | 8.72% | 6.00% |
| SG&A Expenses | 4.40% | -10.81% | -12.57% | -14.41% | -14.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -193.32% | -192.67% | -291.24% | -98.46% | 55.74% |
| Total Operating Expenses | 3.56% | -3.65% | -3.94% | -3.49% | -0.20% |
| Operating Income | 16.50% | 58.02% | 64.04% | 53.23% | 27.85% |
| Income Before Tax | -21.49% | 32.76% | 86.79% | 121.19% | 121.45% |
| Income Tax Expenses | -39.58% | 4.60% | 95.38% | 119.42% | 120.98% |
| Earnings from Continuing Operations | -18.66% | 37.25% | 85.41% | 121.50% | 121.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 15.24% | 18.59% | -13.34% | -56.98% | -73.68% |
| Net Income | -19.02% | 46.45% | 96.69% | 131.02% | 128.01% |
| EBIT | 16.50% | 58.02% | 64.04% | 53.23% | 27.85% |
| EBITDA | 9.16% | 30.39% | 37.83% | 38.21% | 27.19% |
| EPS Basic | -18.13% | 48.29% | 99.03% | 132.20% | 128.62% |
| Normalized Basic EPS | 21.59% | 78.66% | 79.75% | 59.55% | 27.97% |
| EPS Diluted | -18.28% | 47.69% | 98.16% | 131.46% | 128.01% |
| Normalized Diluted EPS | 21.58% | 78.35% | 79.39% | 59.17% | 27.72% |
| Average Basic Shares Outstanding | -1.24% | -1.36% | -1.16% | -0.64% | -0.11% |
| Average Diluted Shares Outstanding | -1.21% | -1.26% | -1.05% | -0.52% | 0.01% |
| Dividend Per Share | 10.70% | 11.90% | 13.53% | 11.65% | 8.08% |
| Payout Ratio | 0.35% | -0.24% | -0.44% | -0.53% | -0.52% |